Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment

References

• Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990–2017. Br J Dermatol. 2021;184(2):1–10. doi:10.1111/bjd.19580.
   PubMed Web of Science ®Google Scholar
• Berke R, Singh A, Guralnick M. Atopic dermatitis: an overview. Am Fam Physician. 2012;86(1):35–42.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–151. doi:10.1016/j.anai.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Carrascosa Carrillo JM, Baselga Torres E, Gilaberte Calzada Y, et al. Quantifying physician preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. Dermatol Ther. 2022;12(5):1197–1210. doi:10.1007/s13555-022-00723-z.
   Web of Science ®Google Scholar
• Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155–1162. doi:10.1016/j.jaci.2022.12.002.
   PubMed Web of Science ®Google Scholar
• Howe W, Paller AS, Butala S, et al. Treatment of atopic dermatitis (eczema). UpToDate Waltham. 2022;MA2021 [updated 2022 Oct 18]. Available from: https://www.uptodate.com/contents/treatment-of-atopic-dermatitis-eczema/print?search=atopic
   Google Scholar
• Blauvelt A, Gooderham M, Bhatia N, et al. Tralokinumab efficacy and safety, with or without topical corticosteroids, in North American adults with moderate-to-severe atopic dermatitis: a subanalysis of phase 3 trials ECZTRA 1, 2, and 3. Dermatol Ther. 2022;12(11):2499–2516. doi:10.1007/s13555-022-00805-y.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi:10.1001/jamadermatol.2022.0029.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi:10.1111/bjd.19574.
   PubMed Web of Science ®Google Scholar
• Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi:10.1016/j.jaad.2019.07.074.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135–141. doi:10.1016/j.jaci.2018.05.029.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Thyssen J, Fahrbach K, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797–1810. doi:10.1111/jdv.17351.
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Lio P, Weidinger S, et al. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Treat. 2023;34(1):2222201. doi:10.1080/09546634.2023.2222201.
   PubMed Web of Science ®Google Scholar
• Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273–282. doi:10.1016/S0140-6736(22)01199-0.
   PubMed Web of Science ®Google Scholar
• Thomas C, Raibouaa A, Wollenberg A, et al. Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment. BMJ Open. 2022;12(8):e058799. doi:10.1136/bmjopen-2021-058799.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Ho K-A, Fifer S, et al. Patient and physician pre­ferences for atopic dermatitis injection treatments in Japan. J Dermatolog Treat. 2020;31(8):821–830. doi:10.1080/09546634.2019.1623860.
   PubMed Web of Science ®Google Scholar
• Myers K, Silverberg JI, Parasuraman S, et al. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Treat. 2023;34(1):2215356. doi:10.1080/09546634.2023.2215356.
   PubMed Web of Science ®Google Scholar
• Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024;104:adv24339. doi:10.2340/actadv.v104.24339.
   PubMedGoogle Scholar
• Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–1112. doi:10.1056/NEJMoa2019380.
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–413. doi:10.1016/j.jval.2010.11.013.
   PubMed Web of Science ®Google Scholar
• Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Adam DN, Zirwas M, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23(4):547–559. doi:10.1007/s40257-022-00702-2.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa1610020.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740–748. doi:10.1093/bjd/ljad022.
   PubMed Web of Science ®Google Scholar
• Steven R, Feldman AG, Gauthier-Loiselle M, et al. Understanding patient experience and factors influencing patient preference in the treatment of moderate-to-severe atopic dermatitis through in-depth qualitative patient interviews. Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; 2023 Apr 29–May 1; Washington, DC.
   Google Scholar
• ChoiceMetrics. Ngene 1.1.1 user manual & reference guide. Sydney (Australia): ChoiceMetrics; 2012.
   Google Scholar
• Johnson FR, Yang JC, Reed SD. The internal validity of discrete choice experiment data: a testing tool for quantitative assessments. Value Health. 2019;22(2):157–160. doi:10.1016/j.jval.2018.07.876.
   PubMed Web of Science ®Google Scholar
• Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient. 2019;12(3):287–295. doi:10.1007/s40271-019-00360-3.
   PubMedGoogle Scholar
• Boeri M, Sutphin J, Hauber B, et al. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatolog Treat. 2022;33(3):1449–1458. doi:10.1080/09546634.2020.1832185.
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590. doi:10.1016/j.jid.2018.08.028.
   PubMed Web of Science ®Google Scholar